2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06B.09 The Role of Cytokines in Predicting the Efficacy of Immunotherapy in Advanced NSCLC Patient

Pdf Summary

The study explores the potential of cytokines as biomarkers to predict the efficacy of immune checkpoint inhibitors (ICIs) in treating advanced non-small cell lung cancer (NSCLC). The research, conducted at Chongqing University Three Gorges Hospital, examined 53 patients diagnosed with advanced NSCLC who received a combination of programmed cell death protein-1 (PD-1) inhibitors and platinum-based chemotherapy. The PD-1 inhibitors used include tislelizumab, camrelizumab, and pembrolizumab, administered over 4-6 treatment cycles.<br /><br />Patients were categorized into partial response (PR), stable disease (SD), and progressive disease (PD) groups to evaluate the correlation between cytokine levels and tumor response, as well as patient survival. The study found that IL-6 levels in the PR and SD groups were significantly lower than in the PD group, indicating its potential as a predictive marker. Furthermore, reductions in the cytokines IL-5, IL-17A, TNF-α, INFα, and IFN-γ after two or four treatment cycles were associated with better prognoses.<br /><br />The patient cohort mostly comprised males (96.23%), with the majority having lung squamous cell carcinoma (LUSC, 56.60%) or lung adenocarcinoma (LUAD, 35.84%). Most participants received tislelizumab (86.79%) as part of their therapy. Significant findings from the baseline include the predominance of stage IIIA/IIIB and IV NSCLC among participants.<br /><br />In conclusion, this study highlights cytokines' promising role as indicators for predicting the efficacy of ICIs in NSCLC treatment. The research is ongoing, with further patient enrollment and follow-up necessary to validate these preliminary findings. This insight into biomarker development could improve personalized treatment strategies for NSCLC patients.

Asset Subtitle

Wei Wang

Meta Tag

Speaker Wei Wang

Topic Pathology and Biomarkers

Keywords

cytokines

biomarkers

immune checkpoint inhibitors

NSCLC

PD-1 inhibitors

tumor response

IL-6

prognosis

personalized treatment

Chongqing University Three Gorges Hospital